The BIOSECURE Act’s Potential Impact on the Biotechnology Supply Chain, July 10

Taking a page out of playbook used to establish the framework that excludes products of certain Chinese telecommunications companies from the federal market (e.g., the “Huawei ban”), the BIOSECURE Act would prohibit the federal government from purchasing biotechnology equipment or services from certain “companies of concern.”  The Act does not stop there.  It would also prohibit Executive agencies from contracting with a company that would use biotechnology equipment or services from a “biotechnology company of concern” in the performance of a federal contract.

Please join the Coalition for a webinar on July 10 from 11:30am – 12:30pm EST as we host four attorneys from Hogan Lovells’ Global Regulatory practice. Partners Joy Sturm, Mike Druckman, Ajay Kuntamukkala, and Tim Bergreen, Senior Counsel, will brief attendees on the latest regarding the BIOSECURE Act.  They will outline what contractors need to know about the Act, including the key terminology, scope, and applicability, and will speak to its implications within the biotechnology sector.  They will also speak about potential U.S. trade sanctions that could be applied to restrict business with companies of concern and others considered to pose a national security threat. Finally, the team will discuss key compliance practices and steps companies can take to keep up with the evolving landscape impacting the biotechnology supply chain.

To register, click here